With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares leading brokers have named as buys this week are listed below. Here's why they are bullish on them:
Appen Ltd (ASX: APX)
According to a note out of Citi, its analysts have retained their buy rating and $17.10 price target on this artificial intelligence data services company's shares. Citi is sticking with Appen despite news that Amazon has launched a new SageMaker Ground Truth Plus service that uses an expert workforce to deliver high-quality training datasets faster. The broker believes that while competition in the Enterprise space may increase, competition with Appen's major technology customers shouldn't be impacted. The Appen share price is trading at $9.21 on Monday afternoon.
Australia and New Zealand Banking GrpLtd (ASX: ANZ)
A note out of Morgans reveals that its analysts have retained their add rating and $31.00 price target on this banking giant's shares. Morgans remains positive on the banking sector as a whole and believes there is potential for further capital management and generous dividends in the near term. Its analysts also expect rising interest rates to be supportive of earnings growth in the coming years. The ANZ share price is fetching $26.87 today.
ResMed Inc. (ASX: RMD)
Analysts at Macquarie have upgraded this medical device company's shares to an outperform rating with a $39.00 price target. While Macquarie acknowledges that supply chain issues are putting pressure on near term device supply, its analysts remain positive. This is due to an expected increase in industry volume growth from 2023 and market share gains for ResMed. Macquarie believes this will support revenue and earnings growth ahead of current analyst consensus estimates. The ResMed share price is trading at $36.29 on Monday.
